Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal TumorsWei‐Ting Liao, Qiu Li, David W. Hutton et al.|Frontiers in Oncology|2021Cited by 1